In fact, KRAS mutational status has been associated with increased PD-L1 expression in non-small-cell lung cancers (NSCLC)59, and anti-PD-1 therapy responses in NSCLC have been correlated with KRAS mutations occurring alone or together with TP53 loss60. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.